BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405. [PMID: 10228190 DOI: 10.1056/NEJM199905063401804] [Cited by in Crossref: 1868] [Cited by in F6Publishing: 408] [Article Influence: 81.2] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Lee MJ, Brown SR, Fearnhead NS, Hart A, Lobo AJ;  PCD Collaborators . How are we managing fistulating perianal Crohn's disease? Frontline Gastroenterol. 2018;9:16-22. [PMID: 29484156 DOI: 10.1136/flgastro-2017-100866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
4 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Reference Citation Analysis]
5 Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52. [PMID: 19440565 DOI: 10.1155/2009/180840] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
6 Gao SJ, Shi RH. Recent progress in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2012; 20(36): 3742-3747 [DOI: 10.11569/wcjd.v20.i36.3742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. Clin Gastroenterol Hepatol 2021;19:238-245.e4. [PMID: 32569749 DOI: 10.1016/j.cgh.2020.06.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Rayen J, Currie T, Gearry RB, Frizelle F, Eglinton T. The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease. Tech Coloproctol 2017;21:119-24. [PMID: 28066859 DOI: 10.1007/s10151-016-1578-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Safar B, Sands D. Perianal Crohn's disease. Clin Colon Rectal Surg 2007;20:282-93. [PMID: 20011424 DOI: 10.1055/s-2007-991027] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gecse K, Khanna R, Stoker J, Jenkins JT, Gabe S, Hahnloser D, D'Haens G. Fistulizing Crohn's disease: Diagnosis and management. United European Gastroenterol J. 2013;1:206-213. [PMID: 24917961 DOI: 10.1177/2050640613487194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
11 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
12 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
13 Hasegawa S, Ichiyama T, Sonaka I, Ohsaki A, Hirano R, Haneda Y, Fukano R, Hara M, Furukawa S. Amino acids exhibit anti-inflammatory effects in human monocytic leukemia cell line, THP-1 cells. Inflamm Res 2011;60:1013-9. [PMID: 21785859 DOI: 10.1007/s00011-011-0362-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
14 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
15 Bagul A. Ischaemic/reperfusion injury: Role of infliximab. World J Transplant 2012; 2(3): 35-40 [PMID: 24175194 DOI: 10.5500/wjt.v2.i3.35] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009;27:455-464. [PMID: 19897960 DOI: 10.1159/000235851] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
18 Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw 2017;17:25-40. [PMID: 28261018 DOI: 10.4110/in.2017.17.1.25] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 25.8] [Reference Citation Analysis]
19 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58:940-948. [PMID: 19201775 DOI: 10.1136/gut.2008.159251] [Cited by in Crossref: 240] [Cited by in F6Publishing: 196] [Article Influence: 18.5] [Reference Citation Analysis]
21 Abramowitz L, Brochard C, Pigot F, Roumeguere P, Pillant H, Vinson Bonnet B, Faucheron JL, Senéjoux A, Bonnaud G, Meurette G, Fayette JM, Train C, Staumont G, Siproudhis L, Bouchard D. Surgical closure, mainly with glue injection and anti-tumour necrosis factor α, in fistulizing perianal Crohn's disease: A multicentre randomized controlled trial. Colorectal Dis 2021. [PMID: 34623746 DOI: 10.1111/codi.15947] [Reference Citation Analysis]
22 Agrawal G, Borody T, Turner R, Leis S, Campbell J. Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease. Future Sci OA 2015;1:FSO77. [PMID: 28031926 DOI: 10.4155/fso.15.77] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
23 Eloy P, Leruth E, Goffart Y, Nollevaux MC, Fridman V, Dartevelle M, Melange M, Daele J, Bertrand B. Sinonasal involvement as a rare extraintestinal manifestation of Crohn's disease. Eur Arch Otorhinolaryngol 2007;264:103-8. [PMID: 17021783 DOI: 10.1007/s00405-006-0146-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Reinisch W, Travis S, Hanauer S, Wang H, Shara N, Harris MS. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis 2014;20:872-81. [PMID: 24694794 DOI: 10.1097/MIB.0000000000000031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Siegmund B, Zeitz M. Standards of medical treatment and nutrition in Crohn's disease. Langenbecks Arch Surg 2005;390:503-9. [PMID: 15449064 DOI: 10.1007/s00423-004-0498-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Reference Citation Analysis]
27 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
28 Lewis RT, Bleier JI. Surgical treatment of anorectal crohn disease. Clin Colon Rectal Surg. 2013;26:90-99. [PMID: 24436656 DOI: 10.1055/s-0033-1348047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
29 Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794. [PMID: 21328309 DOI: 10.1002/14651858.cd008794.pub2] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 17.2] [Reference Citation Analysis]
30 Grünewald J, Tsao ML, Perera R, Dong L, Niessen F, Wen BG, Kubitz DM, Smider VV, Ruf W, Nasoff M, Lerner RA, Schultz PG. Immunochemical termination of self-tolerance. Proc Natl Acad Sci U S A 2008;105:11276-80. [PMID: 18685087 DOI: 10.1073/pnas.0804157105] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
31 Brenmoehl J, Falk W, Göke M, Schölmerich J, Rogler G. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int J Colorectal Dis. 2008;23:947-955. [PMID: 18633626 DOI: 10.1007/s00384-008-0523-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
32 Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY. Mucinous carcinoma in Crohn’s disease originating in a fistulous tract. World J Gastrointest Oncol 2010; 2(7): 307-310 [PMID: 21160662 DOI: 10.4251/wjgo.v2.i7.307] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
33 Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells 2021;10:111. [PMID: 33435303 DOI: 10.3390/cells10010111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Banić M, Anić B, Brkić T, Ljubicić N, Plesko S, Dohoczky C, Erceg D, Petrovecki M, Stipancić I, Rotkvić I. Effect of cyclosporine in a murine model of experimental colitis. Dig Dis Sci. 2002;47:1362-1368. [PMID: 12064814 DOI: 10.1023/A:1015339018181] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013;9:765-79. [PMID: 24273556 DOI: 10.5114/aoms.2013.38670] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
36 Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, Guidi L. Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol 2015; 21(5): 1394-1403 [PMID: 25663759 DOI: 10.3748/wjg.v21.i5.1394] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
37 Buscail E, Le Cosquer G, Gross F, Lebrin M, Bugarel L, Deraison C, Vergnolle N, Bournet B, Gilletta C, Buscail L. Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn's Disease: Rationale, Clinical Results and Perspectives. Int J Mol Sci 2021;22:9967. [PMID: 34576129 DOI: 10.3390/ijms22189967] [Reference Citation Analysis]
38 Laureti S, Gionchetti P, Cappelli A, Vittori L, Contedini F, Rizzello F, Golfieri R, Campieri M, Poggioli G. Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. Inflamm Bowel Dis 2020;26:321-30. [PMID: 31220252 DOI: 10.1093/ibd/izz051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
39 Horaist C, de Parades V, Abramowitz L, Benfredj P, Bonnaud G, Bouchard D, Fathallah N, Sénéjoux A, Siproudhis L, Staumont G, Viguier M, Marteau P. Elaboration and validation of Crohn’s disease anoperineal lesions consensual definitions. World J Gastroenterol 2017; 23(29): 5371-5378 [PMID: 28839437 DOI: 10.3748/wjg.v23.i29.5371] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
40 Kanaan Z, Ahmad S, Bilchuk N, Vahrenhold C, Pan J, Galandiuk S. Perianal Crohn's disease: predictive factors and genotype-phenotype correlations. Dig Surg 2012;29:107-14. [PMID: 22440928 DOI: 10.1159/000335745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
41 Stopfer P, Obermeier F, Dunger N, Falk W, Farkas S, Janotta M, Möller A, Männel DN, Hehlgans T. Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin Exp Immunol. 2004;136:21-29. [PMID: 15030510 DOI: 10.1111/j.1365-2249.2004.02402.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
42 Cima RR, Wolff BG. Reoperative Crohn's surgery: tricks of the trade. Clin Colon Rectal Surg. 2007;20:336-343. [PMID: 20011431 DOI: 10.1055/s-2007-991034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
44 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Jeon M, Song K, Koo J, Kim S. Evaluation of a Seton Procedure Combined With Infliximab Therapy (Early vs. Late) in Perianal Fistula With Crohn Disease. Ann Coloproctol. 2019;35:249-253. [PMID: 31726000 DOI: 10.3393/ac.2018.11.23.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
48 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
49 Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med. 2015;21:730-738. [PMID: 26121193 DOI: 10.1038/nm.3897] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 18.9] [Reference Citation Analysis]
50 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 13.7] [Reference Citation Analysis]
51 Iesalnieks I, Kilger A, Glass H, Müller-Wille R, Klebl F, Ott C, Strauch U, Piso P, Schlitt HJ, Agha A. Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome. Int J Colorectal Dis. 2008;23:1167-1174. [PMID: 18690466 DOI: 10.1007/s00384-008-0534-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
52 Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, Llewellyn SR, Di Narzo A, Kidd BA, Telesco SE, Zhao Y, Stojmirovic A, Sendecki J, Shameer K, Miotto R, Losic B, Shah H, Lee E, Wang M, Faith JJ, Kasarskis A, Brodmerkel C, Curran M, Das A, Friedman JR, Fukui Y, Humphrey MB, Iritani BM, Sibinga N, Tarrant TK, Argmann C, Hao K, Roussos P, Zhu J, Zhang B, Dobrin R, Mayer LF, Schadt EE. A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat Genet 2017;49:1437-49. [PMID: 28892060 DOI: 10.1038/ng.3947] [Cited by in Crossref: 95] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
53 Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6:65-77. [PMID: 25729557 DOI: 10.1177/2040622314563929] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
54 Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509. [PMID: 16188920 DOI: 10.1136/gut.2005.074815] [Cited by in Crossref: 366] [Cited by in F6Publishing: 278] [Article Influence: 21.5] [Reference Citation Analysis]
55 Maconi G, Gridavilla D, Viganò C, Sciurti R, Asthana AK, Furfaro F, Re F, Ardizzone S, Ba G. Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. Int J Colorectal Dis 2014;29:1285-90. [PMID: 24986138 DOI: 10.1007/s00384-014-1935-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
56 Barnes EL, Goldin A, Winter RW, Collins E, Cao B, Carrellas M, Crowell AM, Korzenik JR. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery. Dig Dis Sci 2016;61:3261-9. [PMID: 27639871 DOI: 10.1007/s10620-016-4302-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14:5-14. [PMID: 26884729 DOI: 10.5217/ir.2016.14.1.5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
58 Bouchard D, Pigot F, Staumont G, Siproudhis L, Abramowitz L, Benfredj P, Brochard C, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Vinson-Bonnet B, Laharie D. Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus. Tech Coloproctol 2018;22:905-17. [PMID: 30604249 DOI: 10.1007/s10151-018-1906-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
59 El-Matary W, Walters TD, Huynh HQ, deBruyn J, Mack DR, Jacobson K, Sherlock ME, Church P, Wine E, Carroll MW, Benchimol EI, Lawrence S, Griffiths AM. Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children. Inflamm Bowel Dis. 2019;25:150-155. [PMID: 29912413 DOI: 10.1093/ibd/izy217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
60 Haddow JB, Musbahi O, MacDonald TT, Knowles CH. Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula. World J Gastrointest Pathophysiol 2019; 10(4): 42-53 [PMID: 31750007 DOI: 10.4291/wjgp.v10.i4.42] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
62 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
63 Rogler G. Crohn's disease: Fistulising disease--a problem shared is a problem halved? Nat Rev Gastroenterol Hepatol 2014;11:581-3. [PMID: 25092042 DOI: 10.1038/nrgastro.2014.142] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Coburn LA, Gong X, Singh K, Asim M, Scull BP, Allaman MM, Williams CS, Rosen MJ, Washington MK, Barry DP, Piazuelo MB, Casero RA Jr, Chaturvedi R, Zhao Z, Wilson KT. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS One. 2012;7:e33546. [PMID: 22428068 DOI: 10.1371/journal.pone.0033546] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 9.7] [Reference Citation Analysis]
65 Marchetti M, Liberato NL, Di Sabatino A, Corazza GR. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ 2013;14:853-61. [PMID: 22975794 DOI: 10.1007/s10198-012-0430-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
66 Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
67 Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007;10:178-184. [PMID: 17547856 DOI: 10.1007/s11938-007-0011-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
68 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
69 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
70 Baran B, Karaca C. Practical medical management of Crohn's disease. ISRN Gastroenterol 2013;2013:208073. [PMID: 24307950 DOI: 10.1155/2013/208073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
71 Kim MJ, Choe YH. Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr 2010;53:830-3. [PMID: 21189967 DOI: 10.3345/kjp.2010.53.9.830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
72 Hermann J, Banasiewicz T, Kołodziejczak B. Role of Vacuum-Assisted Closure in the Management of Crohn Anal Fistulas. Adv Skin Wound Care 2019;32:35-40. [PMID: 30540570 DOI: 10.1097/01.ASW.0000547411.16017.58] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Araki T, Okita Y, Fujikawa H, Ohi M, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Redo Ileal pouch-anal anastomosis combined with anti-TNF-α maintenance therapy for Crohn's disease with pelvic fistula: report of two cases. Surg Today 2014;44:1982-5. [PMID: 24442570 DOI: 10.1007/s00595-014-0831-6] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
74 Lin X, Fan D, Cai Z, Lian L, He X, Zhi M, Wu X, He X, Lan P. Similar outcomes for anti-tumor necrosis factor-α antibody and immunosuppressant following seton drainage in patients with Crohn's disease-related anal fistula. Exp Ther Med 2016;12:1939-45. [PMID: 27588113 DOI: 10.3892/etm.2016.3552] [Reference Citation Analysis]
75 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
76 Hadji H, Bouchemal K. Advances in the Treatment of Inflammatory Bowel Disease: Focus on Polysaccharide Nanoparticulate Drug Delivery Systems. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2021.114101] [Reference Citation Analysis]
77 Vuyyuru SK, Desai D, Kedia S, Dhoble P, Sahu P, Kante B, Agarwal S, Bopanna S, Dhingra R, Venigalla PM, Sharma R, Gupta SD, Makharia G, Sahni P, Ahuja V. Long-term outcomes of anti-tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease. JGH Open 2021;5:420-7. [PMID: 33860091 DOI: 10.1002/jgh3.12370] [Reference Citation Analysis]
78 Sica GS, Di Carlo S, Tema G, Montagnese F, Del Vecchio Blanco G, Fiaschetti V, Maggi G, Biancone L. Treatment of peri-anal fistula in Crohn's disease. World J Gastroenterol 2014; 20(37): 13205-13210 [PMID: 25309057 DOI: 10.3748/wjg.v20.i37.13205] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
79 Brannigan AE, Watson RW, Beddy D, Hurley H, Fitzpatrick JM, O'Connell PR. Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann Surg. 2002;235:507-511. [PMID: 11923606 DOI: 10.1097/00000658-200204000-00008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
80 Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
81 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
82 Cima RR, Pemberton JH. Surgical Management of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2001;4:215-25. [PMID: 11469979 DOI: 10.1007/s11938-001-0034-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
83 Athanasiadis S, Yazigi R, Köhler A, Helmes C. Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. Int J Colorectal Dis 2007;22:1051-60. [PMID: 17404747 DOI: 10.1007/s00384-007-0294-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
84 Kothari C, Diorio C, Durocher F. The Importance of Breast Adipose Tissue in Breast Cancer. Int J Mol Sci 2020;21:E5760. [PMID: 32796696 DOI: 10.3390/ijms21165760] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
85 Ledford DK. Clinical trials review: vasculitis. Curr Rheumatol Rep 2000;2:365-8. [PMID: 11123084 DOI: 10.1007/s11926-000-0034-6] [Reference Citation Analysis]
86 Pellino G, Selvaggi F. Surgical treatment of perianal fistulizing Crohn's disease: from lay-open to cell-based therapy--an overview. ScientificWorldJournal 2014;2014:146281. [PMID: 25431776 DOI: 10.1155/2014/146281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
87 Neri P, Lettieri M, Fortuna C, Zucchi M, Manoni M, Celani S, Giovannini A. Adalimumab (humira™) in ophthalmology: a review of the literature. Middle East Afr J Ophthalmol 2010;17:290-6. [PMID: 21180427 DOI: 10.4103/0974-9233.71588] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
88 Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2005;20:1-8. [PMID: 15459771 DOI: 10.1007/s00384-004-0634-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
89 Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-jeangirard C, Lessard M, Baumann R, Freyssinet J, Grunebaum L. Circulating Cell-Derived Microparticles in Crohn?s Disease. Dig Dis Sci 2005;50:574-80. [DOI: 10.1007/s10620-005-2477-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
90 Ryan JJ, Morales JK, Falanga YT, Fernando JF, Macey MR. Mast cell regulation of the immune response. World Allergy Organ J 2009;2:224-32. [PMID: 23283207 DOI: 10.1097/WOX.0b013e3181c2a95e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Scharl M, Rogler G, Biedermann L. Fistulizing Crohn's Disease. Clin Transl Gastroenterol. 2017;8:e106. [PMID: 28703786 DOI: 10.1038/ctg.2017.33] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
92 Click RE. Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases. Virulence 2011;2:131-43. [PMID: 21460639 DOI: 10.4161/viru.2.2.15647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
93 Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, De Vos M, Van den Bosch F, Elewaut D. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020;16:415-33. [PMID: 32661321 DOI: 10.1038/s41584-020-0454-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
94 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
95 Hong L, Zhang C, Fan R, Wang L, Wang Z, Zhang T, Zhong J. Infliximab for Crohn's Disease Patients with Perianal Fistulas: Better Image, Better Life. Med Sci Monit 2020;26:e925018. [PMID: 32785211 DOI: 10.12659/MSM.925018] [Reference Citation Analysis]
96 Basu A, Wexner SD. Perianal Crohn's Disease. Curr Treat Options Gastroenterol. 2002;5:197-206. [PMID: 12003714 DOI: 10.1007/s11938-002-0041-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
97 Alessandroni L, Kohn A, Cosintino R, Marrollo M, Papi C, Monterubbianesi R, Tersigni R. Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study. Tech Coloproctol 2011;15:407-12. [PMID: 22011835 DOI: 10.1007/s10151-011-0759-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
98 Person B, Wexner SD. Management of Perianal Crohn's Disease. Curr Treat Options Gastroenterol 2005;8:197-209. [PMID: 15913509 DOI: 10.1007/s11938-005-0012-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Song YD, Liu SX, Zhong YQ. Biological agents for treatment of inflammatory bowel disease: Research progress and associated risks. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2964-2973 [DOI: 10.11569/wcjd.v24.i19.2964] [Reference Citation Analysis]
100 Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takesue Y, Takahashi Y, Matsumoto T, Tomita N. Long-term efficacy of infliximab maintenance therapy for perianal Crohn’s disease. World J Gastroenterol 2011; 17(9): 1174-1179 [PMID: 21448422 DOI: 10.3748/wjg.v17.i9.1174] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
101 Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn’s disease. Tech Coloproctol. 2009;13:295-300. [PMID: 19774438 DOI: 10.1007/s10151-009-0538-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
102 Sordo-Mejia R, Gaertner WB. Multidisciplinary and evidence-based management of fistulizing perianal Crohn’s disease. World J Gastrointest Pathophysiol 2014; 5(3): 239-251 [PMID: 25133026 DOI: 10.4291/wjgp.v5.i3.239] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
103 Quinn DN, Pfeil SA. Gastroenterology. Clinics in Podiatric Medicine and Surgery 2002;19:23-42. [DOI: 10.1016/s0891-8422(03)00079-x] [Reference Citation Analysis]
104 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
105 Meijer MJ, Mieremet-Ooms MA, Hogezand RAV, Lamers CB, Hommes DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13(21): 2960-2966 [PMID: 17589947 DOI: 10.3748/wjg.v13.i21.2960] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
106 Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60:660-669. [PMID: 11406520 DOI: 10.1136/ard.60.7.660] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 3.9] [Reference Citation Analysis]
107 Galie KL, Whitlow CB. Postoperative enterocutaneous fistula: when to reoperate and how to succeed. Clin Colon Rectal Surg 2006;19:237-46. [PMID: 20011327 DOI: 10.1055/s-2006-956446] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
108 El-Hajj II, Abdul-Baki H, El-Zahabi LM, Barada KA. Primary coloduodenal fistula in Crohn's disease. Dig Dis Sci 2007;52:59-63. [PMID: 17180466 DOI: 10.1007/s10620-006-9227-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
109 Hale LP, Cianciolo G. Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. J Inflamm (Lond) 2008;5:4. [PMID: 18331642 DOI: 10.1186/1476-9255-5-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
110 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
111 Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther 2015;97:22-8. [PMID: 25670380 DOI: 10.1002/cpt.6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
112 Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Am J Gastroenterol 2017;112:120-31. [PMID: 27958281 DOI: 10.1038/ajg.2016.569] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
113 Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis 2013;19:2625-33. [PMID: 24108113 DOI: 10.1097/01.MIB.0000437043.36338.21] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
114 Uzzan S, Azab AN. Anti-TNF-α Compounds as a Treatment for Depression. Molecules 2021;26:2368. [PMID: 33921721 DOI: 10.3390/molecules26082368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406-410. [PMID: 15309501 DOI: 10.1007/s00296-004-0467-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 4.3] [Reference Citation Analysis]
116 de Groof EJ, Buskens CJ, Ponsioen CY, Dijkgraaf MG, D'Haens GR, Srivastava N, van Acker GJ, Jansen JM, Gerhards MF, Dijkstra G, Lange JF, Witteman BJ, Kruyt PM, Pronk A, van Tuyl SA, Bodelier A, Crolla RM, West RL, Vrijland WW, Consten EC, Brink MA, Tuynman JB, de Boer NK, Breukink SO, Pierik MJ, Oldenburg B, van der Meulen AE, Bonsing BA, Spinelli A, Danese S, Sacchi M, Warusavitarne J, Hart A, Yassin NA, Kennelly RP, Cullen GJ, Winter DC, Hawthorne AB, Torkington J, Bemelman WA. Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. Trials 2015;16:366. [PMID: 26289163 DOI: 10.1186/s13063-015-0831-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
117 Marques S, Garcia-gonzalo J, Botequim B, Ricardo A, Borges J, Tome M, Oliveira M. Assessing wildfire occurrence probability in Pinus pinaster Ait. stands in Portugal. Forest Syst 2012;21:111. [DOI: 10.5424/fs/2112211-11374] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
118 Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92-106. [PMID: 19153563 DOI: 10.1038/ncpgasthep1340] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
119 Forte D, Ciciarello M, Valerii MC, De Fazio L, Cavazza E, Giordano R, Parazzi V, Lazzari L, Laureti S, Rizzello F, Cavo M, Curti A, Lemoli RM, Spisni E, Catani L. Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis. Stem Cell Res Ther 2015;6:170. [PMID: 26353774 DOI: 10.1186/s13287-015-0166-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
120 Cheng LE, Kanwar B, Tcheurekdjian H, Grenert JP, Muskat M, Heyman MB, McCune JM, Wara DW. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol. 2009;132:124-131. [PMID: 19375390 DOI: 10.1016/j.clim.2009.03.514] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
121 Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vaccin Immunother 2017;13:1-10. [PMID: 28301271 DOI: 10.1080/21645515.2017.1286433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
122 Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Therap Adv Gastroenterol. 2010;3:179-189. [PMID: 21180600 DOI: 10.1177/1756283x09357579] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
123 Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43. [PMID: 12077089 DOI: 10.1136/gut.51.1.37] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 6.6] [Reference Citation Analysis]
124 Vasudevan A, Bruining DH, Loftus EV Jr, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol 2021; 27(25): 3693-3704 [PMID: 34321838 DOI: 10.3748/wjg.v27.i25.3693] [Reference Citation Analysis]
125 Wu Q, Li B, Li Z, Li J, Sun S, Sun S. Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol 2019;12:95. [PMID: 31500658 DOI: 10.1186/s13045-019-0778-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 26.0] [Reference Citation Analysis]
126 Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Dig Dis Sci. 2004;49:1458-1460. [PMID: 15481319 DOI: 10.1023/b:ddas.0000042246.58984.98] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
127 Romero-Cara P, Torres-Moreno D, Pedregosa J, Vílchez JA, García-Simón MS, Ruiz-Merino G, Morán-Sanchez S, Conesa-Zamora P. A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF. Int J Med Sci 2018;15:10-5. [PMID: 29333082 DOI: 10.7150/ijms.22812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
128 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
129 Saigusa N, Saigusa JI, Shinozaki M, Yokoyama T, Yokoi Y, Takami H, Miyahara R, Yokoyama Y. A series of seton techniques involving "top-down therapy" for patients with Crohn's disease who initially presented with perianal fistulas. J Anus Rectum Colon 2018;2:122-9. [PMID: 31559354 DOI: 10.23922/jarc.2017-044] [Reference Citation Analysis]
130 Park SH, Aniwan S, Scott Harmsen W, Tremaine WJ, Lightner AL, Faubion WA, Loftus EV. Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. Inflamm Bowel Dis. 2019;25:1054-1060. [PMID: 30346531 DOI: 10.1093/ibd/izy329] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
131 Alrubaiy L, Hutchings HA, Williams JG. Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open 2013;3:e003192. [PMID: 23842503 DOI: 10.1136/bmjopen-2013-003192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
132 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. [PMID: 17299059 DOI: 10.1136/gut.2006.106781] [Cited by in Crossref: 649] [Cited by in F6Publishing: 609] [Article Influence: 43.3] [Reference Citation Analysis]
133 Pinson C, Dolores M, Cruypeninck Y, Koning E, Dacher JN, Savoye G, Savoye-Collet C. Magnetization transfer ratio for the assessment of perianal fistula activity in Crohn’s disease. Eur Radiol. 2017;27:80-87. [PMID: 27085695 DOI: 10.1007/s00330-016-4350-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
134 Jarrot PA, Kaplanski G. Anti-TNF-alpha therapy and systemic vasculitis. Mediators Inflamm 2014;2014:493593. [PMID: 24719524 DOI: 10.1155/2014/493593] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
135 D'haens G. The impact of anti-TNF (Infliximab or RemicadeR) on the surgical management of Crohn's disease. Colorect Dis 2001;3:7-10. [DOI: 10.1046/j.1463-1318.2001.003s2007.x] [Reference Citation Analysis]
136 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
137 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
138 Gribovskaja-Rupp I, Melton GB. Enterocutaneous Fistula: Proven Strategies and Updates. Clin Colon Rectal Surg 2016;29:130-7. [PMID: 27247538 DOI: 10.1055/s-0036-1580732] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
139 Nikolaus S, Schreiber S, Fölsch UR. [Pharmacologic therapy for inflammatory bowel diseases: hopes, disappointments]. Internist (Berl) 2005;46:586-91. [PMID: 15806413 DOI: 10.1007/s00108-005-1386-9] [Reference Citation Analysis]
140 Mueller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002;105:1-8. [PMID: 11849309 DOI: 10.1046/j.1365-2567.2002.01329.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
141 Nikolaus S, Schreiber S. [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease]. Internist (Berl) 2008;49:947-8, 950-3. [PMID: 18584139 DOI: 10.1007/s00108-008-2058-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
142 Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease. Drugs 2018;78:1-18. [PMID: 29139091 DOI: 10.1007/s40265-017-0842-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
143 Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn's disease. Ann Gastroenterol. 2017;30:33-44. [PMID: 28042236 DOI: 10.20524/aog.2016.0099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
144 ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211. [PMID: 11788561 DOI: 10.1136/gut.50.2.206] [Cited by in Crossref: 370] [Cited by in F6Publishing: 358] [Article Influence: 18.5] [Reference Citation Analysis]
145 Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World J Gastroenterol 2020; 26(14): 1554-1563 [PMID: 32327905 DOI: 10.3748/wjg.v26.i14.1554] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Rongey C, Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol 2006; 12(43): 6909-6921 [PMID: 17109510 DOI: 10.3748/wjg.v12.i43.6909] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
147 Adegbola SO, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, Hart A. Review of local injection of anti-TNF for perianal fistulising Crohn's disease. Int J Colorectal Dis. 2017;32:1539-1544. [PMID: 28900730 DOI: 10.1007/s00384-017-2899-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
148 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol 2017;52:535-54. [PMID: 28275925 DOI: 10.1007/s00535-017-1324-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
149 Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2004;49:1-4. [PMID: 14992426 DOI: 10.1023/b:ddas.0000011827.87103.2e] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
150 Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut. 2004;53:1303-1308. [PMID: 15306590 DOI: 10.1136/gut.2003.024190] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 5.4] [Reference Citation Analysis]
151 Everhov ÅH, Kalman TD, Söderling J, Nordenvall C, Halfvarson J, Ekbom A, Ludvigsson JF, Olén O, Myrelid P. Probability of Stoma in Incident Patients With Crohn's Disease in Sweden 2003-2019: A Population-based Study. Inflamm Bowel Dis 2021:izab245. [PMID: 34618020 DOI: 10.1093/ibd/izab245] [Reference Citation Analysis]
152 Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039. [PMID: 15309897 DOI: 10.1023/b:das.0000034568.69407.47] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Lee MJ, Heywood N, Adegbola S, Tozer P, Sahnan K, Fearnhead NS, Brown SR; ENiGMA Collaborators. Systematic review of surgical interventions for Crohn's anal fistula. BJS Open 2017;1:55-66. [PMID: 29951607 DOI: 10.1002/bjs5.13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
154 Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterol J 2018;6:310-21. [PMID: 29511561 DOI: 10.1177/2050640617708952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
155 de Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: A reduced need or delayed verdict? World J Gastroenterol 2012; 18(29): 3828-3832 [PMID: 22876034 DOI: 10.3748/wjg.v18.i29.3828] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
156 Hendler SA, Cohen BL, Colombel JF, Sands BE, Mayer L, Agarwal S. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266-275. [PMID: 25540149 DOI: 10.1093/ecco-jcc/jju026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
157 Singh SM, Rau NV, Cohen LB, Harris H. Cutaneous nocardiosis complicating management of Crohn’s disease with infliximab and prednisone. CMAJ. 2004;171:1063-1064. [PMID: 15505269 DOI: 10.1503/cmaj.1040563] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
158 Rampton DS. Management of Crohn's disease. BMJ. 1999;319:1480-1485. [PMID: 10582935 DOI: 10.1136/bmj.319.7223.1480] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
159 Yaari S, Benson A, Aviran E, Lev Cohain N, Oren R, Sosna J, Israeli E. Factors associated with surgery in patients with intra-abdominal fistulizing Crohn's disease. World J Gastroenterol 2016; 22(47): 10380-10387 [PMID: 28058018 DOI: 10.3748/wjg.v22.i47.10380] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
160 Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J. 2004;80:206-213. [PMID: 15082841 DOI: 10.1136/pgmj.2003.013722] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
161 Liu W, Zhou W. Surgery for inflammatory bowel disease in the era of biologics. Shijie Huaren Xiaohua Zazhi 2021; 29(22): 1311-1315 [DOI: 10.11569/wcjd.v29.i22.1311] [Reference Citation Analysis]
162 Lansdorp CA, Gecse KB, Buskens CJ, Löwenberg M, Stoker J, Bemelman WA, D'Haens GRAM, van Hulst RA. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease. Aliment Pharmacol Ther 2021;53:587-97. [PMID: 33326623 DOI: 10.1111/apt.16228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001;77:436-40. [PMID: 11423591 DOI: 10.1136/pmj.77.909.436] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
164 Burgos-Vargas R. Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis 2002;61 Suppl 3:iii33-9. [PMID: 12381509 DOI: 10.1136/ard.61.suppl_3.iii33] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
165 Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012;27:595-600. [PMID: 22065114 DOI: 10.1007/s00384-011-1350-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 101] [Article Influence: 11.0] [Reference Citation Analysis]
166 Rahbour G, Hart AL, Al-Hassi HO, Ullah MR, Gabe SM, Knight SC, Warusavitarne J, Vaizey CJ. Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. BMC Surg 2011;11:12. [PMID: 21619579 DOI: 10.1186/1471-2482-11-12] [Reference Citation Analysis]
167 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
168 Ramarapu S. Anesthetizing a Patient with Escalating Cardiac Enzyme Levels for Urgent Noncardiac Surgery: Clinical and Ethical Concerns. A A Case Rep 2015;5:29-31. [PMID: 26171740 DOI: 10.1213/XAA.0000000000000168] [Reference Citation Analysis]
169 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
170 Gallego JC, Echarri A. Role of magnetic resonance imaging in the management of perianal Crohn's disease. Insights Imaging 2018;9:47-58. [PMID: 29143190 DOI: 10.1007/s13244-017-0579-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: how much is too much? Curr Opin Gastroenterol 2012;28:341-8. [PMID: 22573191 DOI: 10.1097/MOG.0b013e328354567f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
172 Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut. 2004;53:70-77. [PMID: 14684579 DOI: 10.1136/gut.53.1.70] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 7.1] [Reference Citation Analysis]
173 Kelley KA, Kaur T, Tsikitis VL. Perianal Crohn's disease: challenges and solutions. Clin Exp Gastroenterol. 2017;10:39-46. [PMID: 28223835 DOI: 10.2147/ceg.s108513] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
174 Yan X, Zhu M, Feng Q, Yan Y, Peng J, Xu X, Xu A, Ran Z. Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging. Gastroenterol Rep (Oxf) 2019;7:50-6. [PMID: 30792866 DOI: 10.1093/gastro/goy036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
175 Pang Z, Shen BW, Zheng JJ. Intra-abdominal abscess develops during infliximab treatment of refractory Crohn's disease: a report of one case. Shijie Huaren Xiaohua Zazhi 2009; 17(21): 2221-2222 [DOI: 10.11569/wcjd.v17.i21.2221] [Reference Citation Analysis]
176 Patil SA, Rustgi A, Langenberg P, Cross RK. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci 2013;58:209-15. [PMID: 23014844 DOI: 10.1007/s10620-012-2323-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
177 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
178 Panés J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:652-64. [PMID: 28790453 DOI: 10.1038/nrgastro.2017.104] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
179 Deng F, Xia P, Wu Z, Zhou H, Wang X. Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease. Int J Gen Med 2021;14:3387-96. [PMID: 34285563 DOI: 10.2147/IJGM.S315505] [Reference Citation Analysis]
180 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
181 Reinecke K, Eminel S, Dierck F, Roessner W, Kersting S, Chromik AM, Gavrilova O, Laukevicience A, Leuschner I, Waetzig V. The JNK inhibitor XG-102 protects against TNBS-induced colitis. PLoS One. 2012;7:e30985. [PMID: 22427801 DOI: 10.1371/journal.pone.0030985] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
182 Ishigami J, Taliercio J, I Feldman H, Srivastava A, Townsend R, L Cohen D, Horwitz E, Rao P, Charleston J, Fink JC, Ricardo AC, Sondheimer J, Chen TK, Wolf M, Isakova T, Appel LJ, Matsushita K; CRIC Study Investigators. Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease. Am J Epidemiol 2020;189:433-44. [PMID: 31673705 DOI: 10.1093/aje/kwz246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55:81-5. [PMID: 11864998 DOI: 10.1136/jcp.55.2.81] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
184 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
185 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
186 Yang BL, Zhu P, Sun GD. Diagnosis and treatment of perianal fistulas in Crohn's disease. Shijie Huaren Xiaohua Zazhi 2009; 17(20): 2058-2063 [DOI: 10.11569/wcjd.v17.i20.2058] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Lee T, Kamm MA, Bell S, Lust M, Brown S, Niewiadomski O, Basnayake C, Wright E, D'Souza B, Woods R, Wei SC, Connell W, Thompson A, Yong E, Ding NS. Long-term outcomes of perianal fistulizing Crohn's disease in the biologic era. JGH Open 2021;5:235-41. [PMID: 33553661 DOI: 10.1002/jgh3.12475] [Reference Citation Analysis]
188 Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002;324:14-30. [PMID: 12120821 DOI: 10.1097/00000441-200207000-00004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
189 Wiese DM, Schwartz DA. Managing Perianal Crohn’s Disease. Curr Gastroenterol Rep 2012;14:153-61. [DOI: 10.1007/s11894-012-0243-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
190 Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol 2020;16:32-52. [PMID: 31831878 DOI: 10.1038/s41584-019-0337-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
191 Fefferman DS, Shah SA, Alsahlil M, Gelrud A, Falchulk KR, Farrell RJ. Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 2001;46:1733-5. [PMID: 11508675 DOI: 10.1023/a:1010613823223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
192 Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009; 15(34): 4263-4272 [PMID: 19750568 DOI: 10.3748/wjg.15.4263] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
193 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
194 Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11:1-15. [PMID: 16557334 DOI: 10.2119/2006-00005.dinarello] [Cited by in Crossref: 233] [Cited by in F6Publishing: 117] [Article Influence: 17.9] [Reference Citation Analysis]
195 Johnston SL. Biologic therapies: what and when? J Clin Pathol 2007;60:8-17. [PMID: 17213345 DOI: 10.1136/jcp.2005.032300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
196 Parray FQ, Wani ML, Bijli AH, Thakur N, Irshad I; Nayeem-ul-Hassan. Crohn's disease: a surgeon's perspective. Saudi J Gastroenterol 2011;17:6-15. [PMID: 21196646 DOI: 10.4103/1319-3767.74430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
197 Giuliari GP, Sadaka A, Hinkle DM. Biologic agents in experimental autoimmune uveitis. Int Ophthalmol 2014;34:145-56. [PMID: 23494482 DOI: 10.1007/s10792-013-9756-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
198 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
199 Bouchard D, Abramowitz L, Bouguen G, Brochard C, Dabadie A, de Parades V, Eléouet-Kaplan M, Fathallah N, Faucheron JL, Maggiori L, Panis Y, Pigot F, Rouméguère P, Sénéjoux A, Siproudhis L, Staumont G, Suduca JM, Vinson-Bonnet B, Zeitoun JD. Anoperineal lesions in Crohn's disease: French recommendations for clinical practice. Tech Coloproctol 2017;21:683-91. [PMID: 28929282 DOI: 10.1007/s10151-017-1684-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
200 Wickramanayake DD, Choi JH, Shin J, Oh JW. Generation of single-chain Fv antibody fragments against Mu-2-related death-inducing gene in Escherichia coli. Mol Biol Rep 2019;46:4027-37. [PMID: 31073914 DOI: 10.1007/s11033-019-04852-1] [Reference Citation Analysis]
201 Ruffolo C, Scarpa M, Faggian D, Romanato G, De Pellegrin A, Filosa T, Prando D, Polese L, Scopelliti M, Pilon F, Ossi E, Frego M, D'Amico DF, Angriman I. Cytokine network in chronic perianal Crohn's disease and indeterminate colitis after colectomy. J Gastrointest Surg. 2007;11:16-21. [PMID: 17390181 DOI: 10.1007/s11605-006-0021-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
202 Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010;6:149-57. [PMID: 20173776 DOI: 10.1038/nrendo.2009.275] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
203 Chung MW, Chen CM, Hsu JT, Wu RC, Chiu CT, Kuo CJ, Su MY, Le PH. Vedolizumab combined with surgical resection successfully treated perforating Crohn's disease with peritoneal space to rectal and vaginal fistulas: a case report. BMC Gastroenterol 2021;21:299. [PMID: 34325666 DOI: 10.1186/s12876-021-01875-6] [Reference Citation Analysis]
204 Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, Weisman MH. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 2012;14:R261. [PMID: 23194008 DOI: 10.1186/ar4106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
205 Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
206 Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, van der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters KCMJ, van der Meulen-de Jong AE. Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. J Crohns Colitis. 2020;14:64-70. [PMID: 31197361 DOI: 10.1093/ecco-jcc/jjz116] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
207 Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn’s disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502. [PMID: 21912761 DOI: 10.1155/2011/157604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
208 Bafford AC, Coakley B, Powers S, Greenwald D, Ha CY, Weintraub J, Chessin DB, Gorfine SR, Bauer JJ. The clinical impact of preoperative percutaneous drainage of abdominopelvic abscesses in patients with Crohn's disease. Int J Colorectal Dis 2012;27:953-8. [PMID: 22249438 DOI: 10.1007/s00384-011-1401-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
209 Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep 2018;8:9119. [PMID: 29904166 DOI: 10.1038/s41598-018-27353-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
210 Zheng J, Wang J, Pouliot M, Authier S, Zhou D, Loose DS, Hauer-Jensen M. Gene expression profiling in non-human primate jejunum, ileum and colon after total-body irradiation: a comparative study of segment-specific molecular and cellular responses. BMC Genomics 2015;16:984. [PMID: 26589571 DOI: 10.1186/s12864-015-2168-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
211 Uzzan M, Corcos O, Martin JC, Treton X, Bouhnik Y. Why is SARS-CoV-2 infection more severe in obese men? Med Hypotheses. 2020;144:110023. [PMID: 32593832 DOI: 10.1016/j.mehy.2020.110023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
212 Johnston SL. Clinical immunology review series: an approach to the patient with recurrent superficial abscesses. Clin Exp Immunol 2008;152:397-405. [PMID: 18422735 DOI: 10.1111/j.1365-2249.2008.03640.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
213 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
214 Ishii D, Schenk AD, Baba S, Fairchild RL. Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts. Am J Transplant 2010;10:59-68. [PMID: 19958333 DOI: 10.1111/j.1600-6143.2009.02921.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
215 Smith KA. Medical immunology: a new journal for a new subspecialty. Med Immunol 2002;1:1. [PMID: 12437786 DOI: 10.1186/1476-9433-1-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
216 Park EJ, Song KH, Baik SH, Park JJ, Kang J, Lee KY, Goo JI, Kim NK. The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes. Asian J Surg 2018;41:438-47. [PMID: 28851611 DOI: 10.1016/j.asjsur.2017.06.005] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
217 Adegbola SO, Dibley L, Sahnan K, Wade T, Verjee A, Sawyer R, Mannick S, McCluskey D, Bassett P, Yassin N, Warusavitarne J, Faiz O, Phillips R, Tozer PJ, Norton C, Hart AL. Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale. Gut 2021;70:1649-56. [PMID: 33272978 DOI: 10.1136/gutjnl-2019-320553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
218 Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci. 2010;55:1066-1078. [PMID: 19513841 DOI: 10.1007/s10620-009-0846-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
219 Visschers RG, van Gemert WG, Winkens B, Soeters PB, Olde Damink SW. Guided treatment improves outcome of patients with enterocutaneous fistulas. World J Surg. 2012;36:2341-2348. [PMID: 22669399 DOI: 10.1007/s00268-012-1663-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
220 Im JP. Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease? Intest Res 2017;15:147-8. [PMID: 28522942 DOI: 10.5217/ir.2017.15.2.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
221 Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493. [PMID: 15361500 DOI: 10.1136/gut.2003.035253] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
222 Catt H, Hughes D, Kirkham JJ, Bodger K. Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. Aliment Pharmacol Ther 2019;49:978-96. [PMID: 30828852 DOI: 10.1111/apt.15174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
223 Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
224 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
225 Aaltonen G, Carpelan-Holmström M, Keränen I, Lepistö A. Risk factors for proctectomy in consecutive Crohn's colitis surgical patients in a reference colorectal centre. Int J Colorectal Dis 2019;34:1401-6. [PMID: 31254067 DOI: 10.1007/s00384-019-03337-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Lee T, Yong E, Ding NS. Radiological outcomes in perianal fistulizing Crohn's disease: A systematic review and meta-analysis. JGH Open 2020;4:340-4. [PMID: 32514434 DOI: 10.1002/jgh3.12295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
227 Ruffolo C, Citton M, Scarpa M, Angriman I, Massani M, Caratozzolo E, Bassi N. Perianal Crohn’s disease: Is there something new? World J Gastroenterol 2011; 17(15): 1939-1946 [PMID: 21528071 DOI: 10.3748/wjg.v17.i15.1939] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
228 Song YN, Zheng P, Xiao JH, Lu ZJ. Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol 2014;70:907-14. [PMID: 24880961 DOI: 10.1007/s00228-014-1702-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
229 Wasmann KA, de Groof EJ, Stellingwerf ME, D'Haens GR, Ponsioen CY, Gecse KB, Dijkgraaf MGW, Gerhards MF, Jansen JM, Pronk A, van Tuyl SAC, Zimmerman DDE, Bruin KF, Spinelli A, Danese S, van der Bilt JDW, Mundt MW, Bemelman WA, Buskens CJ. Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial. J Crohns Colitis. 2020;14:1049-1056. [PMID: 31919501 DOI: 10.1093/ecco-jcc/jjaa004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
230 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.04337253/suppl_5/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61. [PMID: 12968979 DOI: 10.1046/j.1365-2125.2003.01965.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
232 Bataille F, Klebl F, Rümmele P, Schroeder J, Farkas S, Wild PJ, Fürst A, Hofstädter F, Schölmerich J, Herfarth H. Morphological characterisation of Crohn’s disease fistulae. Gut. 2004;53:1314-1321. [PMID: 15306592 DOI: 10.1136/gut.2003.038208] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
233 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
234 Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002;4 Suppl 2:S34-40. [PMID: 12110156 DOI: 10.1186/ar552] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
235 Seifarth C, Kreis ME, Gröne J. Indications and Specific Surgical Techniques in Crohn’s Disease. Viszeralmedizin. 2015;31:273-279. [PMID: 26557836 DOI: 10.1159/000438955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
236 Zaboli P, Abdollahi M, Mozaffari S, Nikfar S. Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. J Res Pharm Pract 2017;6:135-44. [PMID: 29026838 DOI: 10.4103/jrpp.JRPP_17_46] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Hernández-Breijo B, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Bermejo F, Beltrán B, Rodríguez-Pescador A, Banales JM, Olivares D, Aguilar-Melero P, Menchén L, Ferreiro-Iglesias R, Blazquez Gómez I, Benitez García B, Guijarro LG, Marin AC, Bernardo D, Marsal S, Julia A, Gisbert JP. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Therap Adv Gastroenterol 2019;12:1756284819867848. [PMID: 31598133 DOI: 10.1177/1756284819867848] [Reference Citation Analysis]
238 García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, Casas-Deza D, Cagigas Fernández C, Martin-Cardona A, El Hajra I, Hernández-Aretxabaleta N, Pérez-Martínez I, Fuentes-Valenzuela E, Jiménez N, Rubín de Célix C, Gutiérrez A, Suárez Ferrer C, Huguet JM, Fernández-Clotet A, González-Vivó M, Del Val B, Castro-Poceiro J, Melcarne L, Dueñas C, Izquierdo M, Monfort D, Bouhmidi A, Ramírez De la Piscina P, Romero E, Molina G, Zorrilla J, Calvino-Suárez C, Sánchez E, Nuñez A, Sierra O, Castro B, Zabana Y, González-Partida I, De la Maza S, Castaño A, Nájera-Muñoz R, Sánchez-Guillén L, Riat Castro M, Rueda JL, Benítez JM, Delgado-Guillena P, Tardillo C, Peña E, Frago-Larramona S, Rodríguez-Grau MC, Plaza R, Pérez-Galindo P, Martínez-Cadilla J, Menchén L, Barreiro-De Acosta M, Sánchez-Aldehuelo R, De la Cruz MD, Lamuela LJ, Marín I, Nieto-García L, López-San Román A, Herrera JM, Chaparro M, Gisbert JP, On Behalf Of The Young Group Of Geteccu. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. J Clin Med 2021;10:4402. [PMID: 34640421 DOI: 10.3390/jcm10194402] [Reference Citation Analysis]
239 Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3146-3152 [PMID: 24696600 DOI: 10.3748/wjg.v20.i12.3146] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
240 Fefferman DS, Shah SA, Alsahlil M, Gelrud A, Falchulk KR, Farrell RJ. Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 2001;46:1733-5. [PMID: 11508675 DOI: 10.1023/a:1010613823223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
241 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
242 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
243 Rubín de Célix Vargas C, Algaba A, Guerra I, Serrano Á, Pérez-Viejo E, Aulló C, Bermejo F. Resources used in the treatment of perianal Crohn's disease and the results in a real-life cohort. Gastroenterol Hepatol 2018;41:353-61. [PMID: 29759924 DOI: 10.1016/j.gastrohep.2018.04.006] [Reference Citation Analysis]
244 Evenson AR, Fischer JE. Current management of enterocutaneous fistula. J Gastrointest Surg. 2006;10:455-464. [PMID: 16504896 DOI: 10.1016/j.gassur.2005.08.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
245 Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005;16:289-92. [PMID: 18159561 DOI: 10.1155/2005/814698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
246 Wheat CL, Ko CW, Clark-Snustad K, Grembowski D, Thornton TA, Devine B. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. BMC Gastroenterol 2017;17:52. [PMID: 28407755 DOI: 10.1186/s12876-017-0602-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
247 Poritz LS, Gagliano GA, McLeod RS, MacRae H, Cohen Z. Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. Int J Colorectal Dis 2004;19:481-5; discussion 486. [PMID: 15168043 DOI: 10.1007/s00384-004-0580-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
248 Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. J Can Assoc Gastroenterol. 2018;1:141-154. [PMID: 31799497 DOI: 10.1093/jcag/gwy047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
249 Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28-37. [PMID: 22720209 DOI: 10.4161/onci.1.1.17938] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 75.0] [Reference Citation Analysis]
250 Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol 2018; 24(25): 2764-2775 [PMID: 29991880 DOI: 10.3748/wjg.v24.i25.2764] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
251 Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33. [PMID: 10834859 DOI: 10.1136/ard.59.6.428] [Cited by in Crossref: 190] [Cited by in F6Publishing: 179] [Article Influence: 8.6] [Reference Citation Analysis]
252 Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 Suppl 1:i36-i58. [PMID: 16481630 DOI: 10.1136/gut.2005.081950c] [Cited by in Crossref: 305] [Cited by in F6Publishing: 242] [Article Influence: 19.1] [Reference Citation Analysis]
253 Wang F, Lin X, Zhao Q, Li J. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol 2015;71:911-9. [PMID: 26022220 DOI: 10.1007/s00228-015-1877-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
254 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Osterman MT, VanDussen KL, Gordon IO, Davis EM, Li K, Simpson K, Ciorba M, Glover SC, Abraham B, Guo X, Yee EU, Allard FD, Perrigoue JG, Claggett B, Shen B, Stappenbeck TS, Liu JJ. Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. Inflamm Bowel Dis 2021;27:677-85. [PMID: 32964238 DOI: 10.1093/ibd/izaa251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Fu Y, Ni J, Chen J, Ma G, Zhao M, Zhu S, Shi T, Zhu J, Huang Z, Zhang J, Chen J. Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease. Mol Ther 2020;28:1214-28. [PMID: 32087149 DOI: 10.1016/j.ymthe.2020.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
257 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
258 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
259 Adegbola SO, Pisani A, Sahnan K, Tozer P, Ellul P, Warusavitarne J. Medical and surgical management of perianal Crohn's disease. Ann Gastroenterol 2018;31:129-39. [PMID: 29507460 DOI: 10.20524/aog.2018.0236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
260 Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005;23:875-88. [PMID: 16153132 DOI: 10.2165/00019053-200523090-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
261 Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01042-9. [PMID: 34597729 DOI: 10.1016/j.cgh.2021.09.028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853. [PMID: 12740341 DOI: 10.1136/gut.52.6.847] [Cited by in Crossref: 186] [Cited by in F6Publishing: 191] [Article Influence: 9.8] [Reference Citation Analysis]
263 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
264 Mutanen A, Pakarinen MP. Perianal Crohn's Disease in Children and Adolescents. Eur J Pediatr Surg 2020;30:395-400. [PMID: 32942329 DOI: 10.1055/s-0040-1716724] [Reference Citation Analysis]
265 De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002;4:525-32. [PMID: 12427369 DOI: 10.1007/s11926-002-0061-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
266 Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
267 Isaacs KL. Crohn's disease of the esophagus. Curr Treat Options Gastroenterol 2007;10:61-70. [PMID: 17298766 DOI: 10.1007/s11938-007-0058-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
268 Lee DH. Risk of Repeat Surgery for Perianal Crohn Disease. Ann Coloproctol 2015;31:169. [PMID: 26576391 DOI: 10.3393/ac.2015.31.5.169] [Reference Citation Analysis]
269 Klag T, Goetz M, Stange EF, Wehkamp J. Medical Therapy of Perianal Crohn’s Disease. Viszeralmedizin. 2015;31:265-272. [PMID: 26557835 DOI: 10.1159/000434664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
270 Gu B, De Gregorio M, Pipicella JL, Vande Casteele N, Andrews JM, Begun J, Connell W, D'Souza B, Gholamrezaei A, Hart A, Liew D, Radford-Smith G, Rimola J, Sutherland T, Toong C, Woods R, Wu Y, Xuan W, Williams AJ, Ng W, Ding NS, Connor S. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open 2021;11:e043921. [PMID: 34210720 DOI: 10.1136/bmjopen-2020-043921] [Reference Citation Analysis]
271 Ding L, Azam M, Lin YH, Sheridan J, Wei S, Gupta G, Singh RK, Pauling MH, Chu W, Tran A, Yu NX, Hu J, Wang W, Long H, Xiang D, Zhu L, Hua SB. Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast. Protein Sci 2010;19:1957-66. [PMID: 20718039 DOI: 10.1002/pro.484] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
272 Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS One. 2012;7:e41797. [PMID: 22848611 DOI: 10.1371/journal.pone.0041797] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
273 Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. Genes Dis 2021;8:38-47. [PMID: 33569512 DOI: 10.1016/j.gendis.2020.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
274 Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J 2019;7:496-506. [PMID: 31065367 DOI: 10.1177/2050640619834464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
275 Jiang A, Zhang W, Wu Q, Jin W, Tang Y, Zhang J, Liu JN. Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex. Appl Microbiol Biotechnol 2014;98:105-14. [PMID: 24113827 DOI: 10.1007/s00253-013-5284-0] [Reference Citation Analysis]
276 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
277 Zeitz J, Fournier N, Labenz C, Biedermann L, Frei P, Misselwitz B, Scharl S, Vavricka SR, Sulz MC, Fried M, Rogler G, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis. 2017;1:172-181. [PMID: 29922674 DOI: 10.1159/000458144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
278 Greer MC, Taylor SA. Perianal Imaging in Crohn Disease: Current Status With a Focus on MRI, From the AJR Special Series on Imaging of Inflammation. AJR Am J Roentgenol 2021. [PMID: 34549607 DOI: 10.2214/AJR.21.26615] [Reference Citation Analysis]
279 Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 2002;37 Suppl 14:78-81. [PMID: 12572871 DOI: 10.1007/BF03326419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
280 Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, He Y, Zeng ZR, Zhang SH, Chen MH. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. Stem Cell Res Ther 2017;8:136. [PMID: 28583202 DOI: 10.1186/s13287-017-0570-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
281 Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61 Suppl 3:iii51-60. [PMID: 12381511 DOI: 10.1136/ard.61.suppl_3.iii51] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
282 Lavazza A, Maconi G. Transperineal ultrasound for assessment of fistulas and abscesses: a pictorial essay. J Ultrasound 2019;22:241-9. [PMID: 31066004 DOI: 10.1007/s40477-019-00381-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Hammami A, Slama AB, Jaziri H, Ameur WB, Mansour IB, Brahem A, Ajmi S, Jemni H, Ksiaa M, Jmaa A. Unusual case of duodenobiliary fistula complicating Crohn's disease successfully treated with Adalimumab. Arab J Gastroenterol 2016;17:188-90. [PMID: 27939339 DOI: 10.1016/j.ajg.2016.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
284 Graham DB, Jager DL, Borum ML. Metastatic Crohn's disease of the face. Dig Dis Sci 2006;51:2062-3. [PMID: 17009111 DOI: 10.1007/s10620-006-9533-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
285 Feng D, Sangster-Guity N, Stone R, Korczeniewska J, Mancl ME, Fitzgerald-Bocarsly P, Barnes BJ. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 2010;185:6003-12. [PMID: 20935208 DOI: 10.4049/jimmunol.1000482] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
286 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
287 van Rijn KL, Meima-van Praag EM, Bossuyt PM, D'Haens GR, Gecse KB, Horsthuis K, Snijder HJ, Tielbeek JAW, Buskens CJ, Stoker J. Fibrosis and MAGNIFI-CD activity index at MRI to predict treatment outcome in perianal fistulising Crohn's disease patients. J Crohns Colitis 2021:jjab168. [PMID: 34644395 DOI: 10.1093/ecco-jcc/jjab168] [Reference Citation Analysis]
288 Otley A, Critch J, Butzner JD. Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy. Paediatr Child Health 2004;9:87-9. [PMID: 19654986 DOI: 10.1093/pch/9.2.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 [PMID: 28533923 DOI: 10.4292/wjgpt.v8.i2.131] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
290 Huffaker RK, Shull BL, Thomas JS. A serious complication following placement of posterior Prolift. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:1383-5. [PMID: 19834758 DOI: 10.1007/s00192-009-0873-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
291 Carter MJ, Lobo AJ, Travis SP; IBD Section; British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.043372] [Cited by in Crossref: 700] [Cited by in F6Publishing: 644] [Article Influence: 38.9] [Reference Citation Analysis]
292 Zhu M, Xu X, Feng Q, Cui Z, Wang T, Yan Y, Ran Z. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease. Dig Dis Sci. 2021;66:1658-1668. [PMID: 32524415 DOI: 10.1007/s10620-020-06398-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
293 Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12(23): 3657-3667 [PMID: 16773681 DOI: 10.3748/wjg.v12.i23.3657] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
294 Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:518-23. [PMID: 14602063 DOI: 10.1007/s11894-003-0043-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
295 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
296 Lansdorp CA, Buskens CJ, Gecse KB, D'Haens GRAM, van Hulst RA. Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn's disease: results of the HOT-REVA pilot study. BJS Open 2021;5:zrab042. [PMID: 34046674 DOI: 10.1093/bjsopen/zrab042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
297 Kim NH, Jung YS, Moon CM, Lee SY, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Huh KC, Yoon SM, Song HJ, Boo SJ, Jang HJ, Kim YS, Lee KM, Shin JE, Park DI. Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res 2014;12:281-6. [PMID: 25374493 DOI: 10.5217/ir.2014.12.4.281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
298 D'Haens G, Daperno M. Advances in medical therapy for Crohn's disease. Curr Gastroenterol Rep 2002;4:506-12. [PMID: 12441041 DOI: 10.1007/s11894-002-0027-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
299 Minderhoud IM, Samsom M, Oldenburg B. Crohn’s disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13(14): 2089-2093 [PMID: 17465453 DOI: 10.3748/wjg.v13.i14.2089] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.0] [Reference Citation Analysis]
300 Feroz SH, Ahmed A, Muralidharan A, Thirunavukarasu P. Comparison of the Efficacy of the Various Treatment Modalities in the Management of Perianal Crohn's Fistula: A Review. Cureus 2020;12:e11882. [PMID: 33415035 DOI: 10.7759/cureus.11882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Petryszyn PW, Paradowski L. Economic implications of biological therapy for Crohn's disease. Prz Gastroenterol 2015;10:197-202. [PMID: 26759625 DOI: 10.5114/pg.2015.55749] [Reference Citation Analysis]
302 Schäfer AO. [Perianal inflammatory diseases : Classification and imaging]. Radiologe 2018;58:344-54. [PMID: 29464273 DOI: 10.1007/s00117-018-0368-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
303 Yang BL, Chen YG, Gu YF, Chen HJ, Sun GD, Zhu P, Shao WJ. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World J Gastroenterol 2015; 21(8): 2475-2482 [PMID: 25741157 DOI: 10.3748/wjg.v21.i8.2475] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
304 Rosen MJ, Moulton DE, Koyama T, Morgan WM, Morrow SE, Herline AJ, Muldoon RL, Wise PE, Polk DB, Schwartz DA. Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal Crohn's disease. Inflamm Bowel Dis. 2010;16:461-468. [PMID: 19637325 DOI: 10.1002/ibd.21067] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
305 Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med 2016;12:1693-704. [PMID: 27588089 DOI: 10.3892/etm.2016.3548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
306 Sands BE. New biologic agents: a critical appraisal. Curr Gastroenterol Rep 1999;1:470-5. [PMID: 10980988 DOI: 10.1007/s11894-999-0005-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
307 Alyami A, Hoad CL, Tench C, Bannur U, Clarke C, Latief K, Argyriou K, Lobo A, Lung P, Baldwin-Cleland R, Sahnan K, Hart A, Limdi JK, Mclaughlin J, Atkinson D, Parker GJM, O'Connor JPB, Little RA, Gowland PA, Moran GW. Quantitative Magnetic Resonance Imaging in Perianal Crohn's Disease at 1.5 and 3.0 T: A Feasibility Study. Diagnostics (Basel) 2021;11:2135. [PMID: 34829482 DOI: 10.3390/diagnostics11112135] [Reference Citation Analysis]
308 Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:R250-5. [PMID: 15743471 DOI: 10.1186/ar1477] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
309 Alós R, Hinojosa J. Timing of surgery in Crohn’s disease: A key issue in the management. World J Gastroenterol 2008; 14(36): 5532-5539 [PMID: 18810772 DOI: 10.3748/wjg.14.5532] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
310 Tracanelli L, Mathieu N, Trilling B, Vergniol J, Pigot F, Faucheron JL. Rectovaginal fistula in Crohn's disease treatment: a low long-term success rate and a high definitive stoma risk after a conservative surgical approach. Tech Coloproctol 2021;25:1143-9. [PMID: 34436729 DOI: 10.1007/s10151-021-02506-8] [Reference Citation Analysis]
311 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
312 Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:563-577. [PMID: 31023087 DOI: 10.1080/17474124.2019.1608818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
313 Yeh H, Kuo CJ, Wu RC, Chen CM, Tsai WS, Su MY, Chiu CT, Le PH. Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report. World J Gastroenterol 2021; 27(5): 442-448 [PMID: 33584075 DOI: 10.3748/wjg.v27.i5.442] [Reference Citation Analysis]
314 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
315 Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M, Kanazawa Y, Shimodaira Y, Horiuchi T, Takahashi S. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity. Immunogenetics. 2013;65:265-271. [PMID: 23358932 DOI: 10.1007/s00251-013-0679-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
316 Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018;12:621-626. [PMID: 29471381 DOI: 10.1093/ecco-jcc/jjy019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
317 Geldof J, Iqbal N, Warusavitarne J, Hart A. The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD. Clin Colon Rectal Surg 2022;35:021-31. [DOI: 10.1055/s-0041-1740035] [Reference Citation Analysis]
318 Yachnin BJ, Mulligan VK, Khare SD, Bailey-Kellogg C. MHCEpitopeEnergy, a Flexible Rosetta-Based Biotherapeutic Deimmunization Platform. J Chem Inf Model 2021;61:2368-82. [PMID: 33900750 DOI: 10.1021/acs.jcim.1c00056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Alnaimat F, Sidhu P, Sarkar S. T-cell targeted therapies in autoimmune diseases. Drug Dev Res 2011;72:585-97. [DOI: 10.1002/ddr.20468] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
320 Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 10.4] [Reference Citation Analysis]
321 Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481-1484. [PMID: 17429728 DOI: 10.1007/s10620-006-9250-x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 125] [Article Influence: 10.2] [Reference Citation Analysis]
322 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
323 Göttgens KW, Smeets RR, Stassen LP, Beets GL, Pierik M, Breukink SO. Treatment of Crohn's disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study. Tech Coloproctol 2015;19:455-9. [PMID: 25975971 DOI: 10.1007/s10151-015-1311-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
324 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
325 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
326 Miranda EF, Nones RB, Kotze PG. Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review. Intest Res 2021;19:255-64. [PMID: 33147899 DOI: 10.5217/ir.2020.00029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12:1249-1254. [PMID: 29939254 DOI: 10.1093/ecco-jcc/jjy087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
328 Luglio G, Cassese G, Amendola A, Rispo A, Maione F, De Palma GD. Novel Approaches to Ileocolic and Perianal Fistulising Crohn's Disease. Gastroenterol Res Pract 2018;2018:3159543. [PMID: 30584421 DOI: 10.1155/2018/3159543] [Reference Citation Analysis]
329 Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease. Patient Prefer Adherence 2012;6:417-26. [PMID: 22723726 DOI: 10.2147/PPA.S31115] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
330 Botti F, Losco A, Viganò C, Oreggia B, Prati M, Contessini Avesani E. Imaging techniques and combined medical and surgical treatment of perianal Crohn’s disease. J Ultrasound. 2015;18:19-35. [PMID: 25767636 DOI: 10.1007/s40477-013-0042-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
331 Wiseman J, Chawla T, Morin F, de Buck van Overstraeten A, Weizman AV. A Multi-Disciplinary Approach to Perianal Fistulizing Crohn's Disease. Clin Colon Rectal Surg 2022;35:051-7. [DOI: 10.1055/s-0041-1740038] [Reference Citation Analysis]
332 Balbas-Martinez V, Ruiz-Cerdá L, Irurzun-Arana I, González-García I, Vermeulen A, Gómez-Mantilla JD, Trocóniz IF. A systems pharmacology model for inflammatory bowel disease. PLoS One 2018;13:e0192949. [PMID: 29513758 DOI: 10.1371/journal.pone.0192949] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
333 Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. J Crohns Colitis 2018;12:905-19. [PMID: 29788248 DOI: 10.1093/ecco-jcc/jjy047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
334 Tozer P, Borowski DW, Gupta A, Yassin N, Phillips R, Hart A. Managing perianal Crohn's fistula in the anti-TNFα era. Tech Coloproctol 2015;19:673-8. [PMID: 26264168 DOI: 10.1007/s10151-015-1332-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
335 Valente MA, Hull TL. Contemporary surgical management of rectovaginal fistula in Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(4): 487-495 [PMID: 25400993 DOI: 10.4291/wjgp.v5.i4.487] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
336 Thompson JS, Iyer KR, DiBaise JK, Young RL, Brown CR, Langnas AN. Short bowel syndrome and Crohn’s disease. J Gastrointest Surg. 2003;7:1069-1072. [PMID: 14675717 DOI: 10.1016/j.gassur.2003.08.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
337 Berkovitch G, Cohen S, Lubetzky R, Singer D, Yerushalmy-Feler A. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD. BMC Pediatr 2021;21:63. [PMID: 33541320 DOI: 10.1186/s12887-021-02526-1] [Reference Citation Analysis]
338 Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn's disease: a systematic review of literature. J Gastrointest Surg 2010;14:66-73. [PMID: 19826882 DOI: 10.1007/s11605-009-1061-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
339 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
340 Nam HS, Lee SY, Kim SJ, Kim JS, Kwon SS, Kim YK, Kim KH, Moon HS, Song JS, Park SH, Kim SC. The soluble tumor necrosis factor-alpha receptor suppresses airway inflammation in a murine model of acute asthma. Yonsei Med J 2009;50:569-75. [PMID: 19718408 DOI: 10.3349/ymj.2009.50.4.569] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
341 Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinhoff U. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest. 2006;116:3195-3203. [PMID: 17124531 DOI: 10.1172/jci28804] [Cited by in Crossref: 114] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
342 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
343 Braun J, Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !? Ann Rheum Dis 2000;59:404-7. [PMID: 10834852 DOI: 10.1136/ard.59.6.404] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
344 Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:R326-34. [PMID: 15225368 DOI: 10.1186/ar1182] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 5.0] [Reference Citation Analysis]
345 van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58 Suppl 1:I114-20. [PMID: 10577987 DOI: 10.1136/ard.58.2008.i114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
346 Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siegert S, Radbruch A, Thiel A, Sieper J. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences. Ann Rheum Dis 2000;59 Suppl 1:i85-9. [PMID: 11053096 DOI: 10.1136/ard.59.suppl_1.i85] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
347 Vagianos C, Malgarinos G, Spyropoulos C, Triantafillidis JK. Entero-vesical fistulas in CROHN'S disease: A case series report and review of the literature. Int J Surg Case Rep. 2017;41:477-480. [PMID: 29546021 DOI: 10.1016/j.ijscr.2017.11.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
348 Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12. [PMID: 11830424 DOI: 10.1136/ard.61.3.207] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
349 Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-131. [PMID: 21710141 DOI: 10.1007/s12178-011-9085-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
350 Kochhar R, Gupta V, Dutta U, Singh K, Kochhar R. Infliximab induced endophthalmitis in a patient of fistulizing Crohn's disease. Indian J Gastroenterol. 2011;30:241-242. [PMID: 21932073 DOI: 10.1007/s12664-011-0130-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
351 Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-7. [PMID: 12379516 DOI: 10.1136/ard.61.11.960] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
352 Hwang JM, Varma MG. Surgery for inflammatory bowel disease. World J Gastroenterol 2008; 14(17): 2678-2690 [PMID: 18461653 DOI: 10.3748/wjg.14.2678] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
353 Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
354 Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut. 2000;47:415-422. [PMID: 10940281 DOI: 10.1136/gut.47.3.415] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 3.2] [Reference Citation Analysis]
355 Ishida K, Inoue T, Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, Abe Y, Takeuchi T, Murano M, Tokioka S, Umegaki E, Higuchi K. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 2013; 19(17): 2676-2682 [PMID: 23674875 DOI: 10.3748/wjg.v19.i17.2676] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
356 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
357 Wright EK, Kamm MA, Dr Cruz P, Hamilton AL, Ritchie KJ, Bell SJ, Brown SJ, Connell WR, Desmond PV, Liew D. Cost-effectiveness of Crohn’s disease post-operative care. World J Gastroenterol 2016; 22(14): 3860-3868 [PMID: 27076772 DOI: 10.3748/wjg.v22.i14.3860] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
358 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
359 El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and predictors of failure in women undergoing repair of Crohn’s related rectovaginal fistula. J Gastrointest Surg. 2010;14:824-829. [PMID: 20232172 DOI: 10.1007/s11605-010-1167-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
360 García-Planella E, Domènech E, Cabré E, Bernal MI, Gassull MA. [Intravenous cyclosporine A in the treatment of refractory Crohn's disease]. Med Clin (Barc) 2002;119:610-2. [PMID: 12433336 DOI: 10.1016/s0025-7753(02)73514-8] [Reference Citation Analysis]
361 Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797-806. [PMID: 23053885 DOI: 10.1007/s10620-012-2405-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
362 Rampton DS. Management of difficult inflammatory bowel disease: where are we now? World J Gastroenterol 2000; 6(3): 315-323 [PMID: 11819588 DOI: 10.3748/wjg.v6.i3.315] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
363 Lee JL, Yoon YS, Yu CS. Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon's Point of View. Ann Coloproctol 2021;37:5-15. [PMID: 33730796 DOI: 10.3393/ac.2021.02.08] [Reference Citation Analysis]
364 Singh K, Chaturvedi R, Barry DP, Coburn LA, Asim M, Lewis ND, Piazuelo MB, Washington MK, Vitek MP, Wilson KT. The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem. 2011;286:3839-3850. [PMID: 21115487 DOI: 10.1074/jbc.m110.176719] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
365 Garrick V, Stenhouse E, Haddock G, Russell RK. A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice. Frontline Gastroenterol 2013;4:152-60. [PMID: 28839719 DOI: 10.1136/flgastro-2012-100160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
366 Puigventós Latorre F. Novedades terapéuticas del año 2000: los retos del médico y del gestor. Medicina Clínica 2001;116:465-8. [DOI: 10.1016/s0025-7753(01)71871-4] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
367 Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709. [PMID: 15082589 DOI: 10.1136/gut.2003.017442] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 7.2] [Reference Citation Analysis]
368 Fichera A, Michelassi F. Surgical treatment of Crohn's disease. J Gastrointest Surg. 2007;11:791-803. [PMID: 17562122 DOI: 10.1007/s11605-006-0068-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
369 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
370 Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58 Suppl 1:I61-4. [PMID: 10577975 DOI: 10.1136/ard.58.2008.i61] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
371 Sou S, Matsui T, Yao T, Naito M, Yorioka M, Beppu T, Nagahama T, Futami K. Differentiating enterocutaneous fistulae from suture abscesses complicating Crohn's disease using oral administration of indocyanine green. J Gastroenterol Hepatol 2006;21:1850-3. [PMID: 17074025 DOI: 10.1111/j.1440-1746.2006.04287.x] [Reference Citation Analysis]
372 Gong J, Wei Y, Gu L, Li Y, Guo Z, Sun J, Ding C, Zhu W, Li N, Li J. Outcome of Surgery for Coloduodenal Fistula in Crohn's Disease. J Gastrointest Surg 2016;20:976-84. [PMID: 26718702 DOI: 10.1007/s11605-015-3065-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
373 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
374 Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: Need for HBV-screening? World J Gastroenterol 2006; 12(6): 974-976 [PMID: 16521231 DOI: 10.3748/wjg.v12.i6.974] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 99] [Article Influence: 6.6] [Reference Citation Analysis]
375 Kish DD, Volokh N, Baldwin WM 3rd, Fairchild RL. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol 2011;186:2117-26. [PMID: 21239709 DOI: 10.4049/jimmunol.1002337] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
376 Cominelli F, Arseneau KO, Rodriguez-Palacios A, Pizarro TT. Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? Cell Mol Gastroenterol Hepatol. 2017;4:19-32. [PMID: 28560286 DOI: 10.1016/j.jcmgh.2017.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
377 Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 2005;7:188-94. [PMID: 15918994 DOI: 10.1007/s11926-996-0038-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
378 Guidi L, Ratto C, Semeraro S, Roberto I, De Vitis I, Papa A, Marzo M, Parello A, Foglietto G, Doglietto GB, Gasbarrini GB, Fedeli G. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008;12:111-7. [PMID: 18545878 DOI: 10.1007/s10151-008-0411-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
379 Mizoguchi E, Subramaniam R, Okada T, Mizoguchi A. A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics (Basel) 2021;11:207. [PMID: 33573291 DOI: 10.3390/diagnostics11020207] [Reference Citation Analysis]
380 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 216] [Article Influence: 39.3] [Reference Citation Analysis]
381 Kersting S, Behrendt V, Kersting J, Reinecke K, Hilgert C, Stricker I, Herdegen T, Janot MS, Uhl W, Chromik AM. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res 2013;6:71-81. [PMID: 23667316 DOI: 10.2147/JIR.S40092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
382 Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707-718. [PMID: 29158574 DOI: 10.1038/nrrheum.2017.187] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 16.0] [Reference Citation Analysis]
383 Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol. 2003;133:38-43. [PMID: 12823276 DOI: 10.1046/j.1365-2249.2003.02193.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 3.9] [Reference Citation Analysis]
384 Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008;43:397-401. [PMID: 18592158 DOI: 10.1007/s00535-008-2165-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
385 Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol 2015; 21(20): 6101-6116 [PMID: 26034347 DOI: 10.3748/wjg.v21.i20.6101] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
386 Kim YL, Park YS, Park EK, Park DR, Choi GS, Ahn SB, Kim SH, Jo YJ. Refractory duodenal Crohn's disease successfully treated with infliximab. Intest Res 2014;12:66-9. [PMID: 25349566 DOI: 10.5217/ir.2014.12.1.66] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
387 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
388 Greenwald DA, Brandt LJ. Inflammatory Bowel Disease After Age 60. Curr Treat Options Gastroenterol. 2003;6:213-225. [PMID: 12744821 DOI: 10.1007/s11938-003-0003-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
389 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
390 Lee JS, Park SY, Thapa D, Choi MK, Chung IM, Park YJ, Yong CS, Choi HG, Kim JA. Grifola frondosa water extract alleviates intestinal inflammation by suppressing TNF-alpha production and its signaling. Exp Mol Med 2010;42:143-54. [PMID: 20054232 DOI: 10.3858/emm.2010.42.2.016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
391 Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, Yin Y, Fuhler GM, van der Laan LJ, van der Woude CJ, Sprengers D, Metselaar HJ, Smits R, Poot RA, Peppelenbosch MP, Pan Q. Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV. Sci Rep 2016;6:25482. [PMID: 27150018 DOI: 10.1038/srep25482] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
392 Braithwaite GC, Lee MJ, Hind D, Brown SR. Prognostic factors affecting outcomes in fistulating perianal Crohn's disease: a systematic review. Tech Coloproctol 2017;21:501-19. [PMID: 28639073 DOI: 10.1007/s10151-017-1647-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
393 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1441-1444 [DOI: 10.11569/wcjd.v12.i6.1441] [Reference Citation Analysis]
394 Causey MW, Nelson D, Johnson EK, Maykel J, Davis B, Rivadeneira DE, Champagne B, Steele SR. An NSQIP evaluation of practice patterns and outcomes following surgery for anorectal abscess and fistula in patients with and without Crohn's disease. Gastroenterol Rep (Oxf) 2013;1:58-63. [PMID: 24759668 DOI: 10.1093/gastro/got001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
395 Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-81. [PMID: 16547695 DOI: 10.1007/s10067-005-0169-y] [Cited by in Crossref: 109] [Cited by in F6Publishing: 101] [Article Influence: 6.8] [Reference Citation Analysis]
396 Roper MT, Trinidad SM, Ramamoorthy SL, Parry LA, Lopez NE, Khaitov S, Steinhagen R, Eisenstein SG. Endorectal Advancement Flaps for Perianal Fistulae in Crohn's Disease: Careful Patient Selection Leads to Optimal Outcomes. J Gastrointest Surg. 2019;23:2277-2284. [PMID: 30980232 DOI: 10.1007/s11605-019-04205-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
397 Poritz LS. How should complex perianal Crohn's disease be treated in the Remicade era. J Gastrointest Surg 2006;10:633-4. [PMID: 16773757 DOI: 10.1007/BF03239968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
398 Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease. World J Gastroenterol 2017; 23(23): 4285-4292 [PMID: 28694669 DOI: 10.3748/wjg.v23.i23.4285] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
399 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
400 Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. [PMID: 16906776 DOI: 10.2165/00003495-200666110-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
401 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
402 Lightner AL. Stem Cell Therapies for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2019;21:16. [PMID: 30955111 DOI: 10.1007/s11894-019-0672-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
403 Matsuzawa F, Homma S, Yoshida T, Shibasaki S, Minagawa N, Shimokuni T, Sakihama H, Kawamura H, Takahashi N, Taketomi A. Successful treatment of rectovaginal fistula and rectal stenosis due to perianal Crohn's disease by dual-port laparoscopic abdominoperineal resection: a report of two cases. Surg Case Rep 2016;2:83. [PMID: 27568377 DOI: 10.1186/s40792-016-0211-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
404 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
405 Hermann J, Eder P, Banasiewicz T, Kołodziejczak B, Łykowska-Szuber L. Palliative treatment of anal fistulas in Crohn's disease. ANZ J Surg 2016;86:148-51. [PMID: 26861622 DOI: 10.1111/ans.13474] [Reference Citation Analysis]
406 Möller B, Villiger PM. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 2006;27:391-408. [PMID: 16738952 DOI: 10.1007/s00281-006-0012-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 5.4] [Reference Citation Analysis]
407 Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs 2006;8:279-302. [PMID: 17037946 DOI: 10.2165/00148581-200608050-00002] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
408 Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, Scharl M. The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One. 2013;8:e78882. [PMID: 24250816 DOI: 10.1371/journal.pone.0078882] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
409 Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM. Stability of infliximab in polyvinyl chloride bags. Am J Health Syst Pharm 2012;69:1509-12. [PMID: 22899746 DOI: 10.2146/ajhp100116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
410 Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49:1036-1039. [PMID: 15309897 DOI: 10.1023/B:DDAS.0000034568.69407.47] [Cited by in Crossref: 61] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
411 Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis 2019;25:820-30. [PMID: 30445504 DOI: 10.1093/ibd/izy327] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
412 Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-878. [PMID: 21091117 DOI: 10.2217/imt.10.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
413 Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-6. [PMID: 24114449 DOI: 10.1208/s12248-013-9534-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
414 Seyfried S, Herold A. Management of Perianal Fistulas in Crohn's Disease. Visc Med. 2019;35:338-343. [PMID: 31934580 DOI: 10.1159/000504103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
415 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Mueller MH, Geis M, Glatzle J, Kasparek M, Meile T, Jehle EC, Kreis ME, Zittel TT. Risk of fecal diversion in complicated perianal Crohn's disease. J Gastrointest Surg. 2007;11:529-537. [PMID: 17436140 DOI: 10.1007/s11605-006-0029-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
417 Stio M, Treves C, Martinesi M, d’Albasio G, Bagnoli S, Bonanomi AG. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn’s disease. Dig Dis Sci. 2004;49:328-335. [PMID: 15104379 DOI: 10.1023/b:ddas.0000017460.90887.11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
418 Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-73. [PMID: 15194570 DOI: 10.1136/ard.2003.018085] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 3.7] [Reference Citation Analysis]
419 Hermann J, Stajgis P, Kołodziejczak B, Eder P, Banasiewicz T. Treatment of Crohn's anal fistulas guided by magnetic resonance imaging. Prz Gastroenterol 2019;14:55-61. [PMID: 30944678 DOI: 10.5114/pg.2019.83426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
420 Su CA, Iida S, Abe T, Fairchild RL. Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. Am J Transplant 2014;14:568-79. [PMID: 24502272 DOI: 10.1111/ajt.12605] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
421 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
422 Manne A, Khan AS, Malik TA. Obesity and Outcome of Crohn's Associated Perianal Fistula Surgery: A Case-Control Study. Gastroenterology Res 2015;8:291-5. [PMID: 27785311 DOI: 10.14740/gr698e] [Reference Citation Analysis]
423 Schubert MC, Sridhar S, Schade RR, Wexner SD. What every gastroenterologist needs to know about common anorectal disorders. World J Gastroenterol 2009; 15(26): 3201-3209 [PMID: 19598294 DOI: 10.3748/wjg.15.3201] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
424 Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17(5): 547-556 [PMID: 21350703 DOI: 10.3748/wjg.v17.i5.547] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
425 Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JR. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. Inflamm Bowel Dis 2021;27:1294-301. [PMID: 33146703 DOI: 10.1093/ibd/izaa282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
426 Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63:1664-1669. [PMID: 15297279 DOI: 10.1136/ard.2003.012450] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 5.0] [Reference Citation Analysis]
427 Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146-53. [PMID: 14678276 DOI: 10.1111/j.1365-2249.2004.02348.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
428 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
429 Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol 2016;9:26-36. [PMID: 26770265 DOI: 10.1177/1756283X15618130] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
430 Brochard C, Landemaine A, L'Heritier AM, Dewitte MP, Tchoundjeu B, Rohou T, Garros A, Bouguen G, Siproudhis L. Anal Fistulas in Severe Perineal Crohn's Disease: Mri Assessment in the Determination of Long-Term Healing Rates. Inflamm Bowel Dis 2018;24:1612-8. [PMID: 29688401 DOI: 10.1093/ibd/izy055] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
431 Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol 2012;3:233. [PMID: 22876246 DOI: 10.3389/fimmu.2012.00233] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
432 Meyer J, Ris F, Parkes M, Davies J. Rectovaginal Fistula in Crohn's Disease: When and How to Operate? Clin Colon Rectal Surg 2022;35:010-20. [DOI: 10.1055/s-0041-1740029] [Reference Citation Analysis]
433 Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-448. [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 6.3] [Reference Citation Analysis]
434 Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol. 2011;31:165-173. [PMID: 21287227 DOI: 10.1007/s10792-011-9430-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
435 Siveke JT, Folwaczny C. Biological response modifiers for the treatment of Crohn's disease. Expert Opin Biol Ther 2004;4:1719-27. [PMID: 15500400 DOI: 10.1517/14712598.4.11.1719] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 Baik SH, Kim WH. A comprehensive review of inflammatory bowel disease focusing on surgical management. J Korean Soc Coloproctol 2012;28:121-31. [PMID: 22816055 DOI: 10.3393/jksc.2012.28.3.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
437 Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis 2008;14:206-16. [PMID: 18282173 DOI: 10.1111/j.1601-0825.2008.01440.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
438 Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics 2018;36:853-65. [PMID: 29667146 DOI: 10.1007/s40273-018-0653-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
439 Chhaya V, Pollok R. The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference? F1000Prime Rep 2013;5:50. [PMID: 24273651 DOI: 10.12703/P5-50] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
440 Miyoshi J, Sofia MA, Pierre JF. The evidence for fungus in Crohn's disease pathogenesis. Clin J Gastroenterol 2018;11:449-56. [PMID: 30027368 DOI: 10.1007/s12328-018-0886-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
441 Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004;6:R535-43. [PMID: 15535831 DOI: 10.1186/ar1440] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 4.8] [Reference Citation Analysis]
442 Scott FI, Osterman MT. Medical management of crohn disease. Clin Colon Rectal Surg 2013;26:67-74. [PMID: 24436652 DOI: 10.1055/s-0033-1348043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
443 Bellizzi A, Anzivino E, Rodio DM, Cioccolo S, Scrivo R, Morreale M, Pontecorvo S, Ferrari F, Di Nardo G, Nencioni L, Carluccio S, Valesini G, Francia A, Cucchiara S, Palamara AT, Pietropaolo V. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J 2013;10:298. [PMID: 24079660 DOI: 10.1186/1743-422X-10-298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
444 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
445 Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94. [PMID: 11781268 DOI: 10.1128/cmr.15.1.79-94.2002] [Cited by in Crossref: 302] [Cited by in F6Publishing: 121] [Article Influence: 15.1] [Reference Citation Analysis]
446 Van den Bosch F, Baeten D, Kruithof E, De Keyser F, Mielants H, Veys EM. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 2001;60 Suppl 3:iii33-6. [PMID: 11890649 DOI: 10.1136/ard.60.90003.iii33] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
447 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
448 Frostberg E, Ström P, Gerke O, Qvist N. Infliximab's influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model. BMC Surg 2014;14:23. [PMID: 24762063 DOI: 10.1186/1471-2482-14-23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
449 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
450 Ashkenazi I, Olsha O, Kessel B, Krausz MM, Alfici R. Uncommon acquired fistulae involving the digestive system: summary of data. Eur J Trauma Emerg Surg 2011;37:259-67. [PMID: 26815108 DOI: 10.1007/s00068-011-0112-7] [Reference Citation Analysis]
451 Coburn LA, Horst SN, Allaman MM, Brown CT, Williams CS, Hodges ME, Druce JP, Beaulieu DB, Schwartz DA, Wilson KT. L-Arginine Availability and Metabolism Is Altered in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1847-58. [PMID: 27104830 DOI: 10.1097/MIB.0000000000000790] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
452 Freire P, Portela F, Donato MM, Ferreira M, Andrade P, Sofia C. CARD15 mutations and perianal fistulating Crohn’s disease: correlation and predictive value of antibiotic response. Dig Dis Sci. 2011;56:853-859. [PMID: 20632099 DOI: 10.1007/s10620-010-1331-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
453 Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, Inoue Y, Ito T. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. Surg Today. 2016;46:922-929. [PMID: 26438200 DOI: 10.1007/s00595-015-1257-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
454 Al-Maawali AK, Nguyen P, Phang PT. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. Can J Gastroenterol Hepatol 2016;2016:1651570. [PMID: 28053967 DOI: 10.1155/2016/1651570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]